دورية أكاديمية
أعرض في EDS

Platelet and Monocyte Activation After Transcatheter Aortic Valve Replacement (POTENT-TAVR): A Mechanistic Randomized Trial of Ticagrelor Versus Clopidogrel.

التفاصيل البيبلوغرافية
العنوان: Platelet and Monocyte Activation After Transcatheter Aortic Valve Replacement (POTENT-TAVR): A Mechanistic Randomized Trial of Ticagrelor Versus Clopidogrel.
المؤلفون: Zidar DA; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.; Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA., Al-Kindi S; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA., Longenecker CT; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA., Parikh SA; Division of Cardiology, Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, New York, USA., Gillombardo CB; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA., Funderburg NT; Division of Medical Laboratory Science, School of Health and Rehabilitations Sciences, Ohio State University, Columbus, Ohio, USA., Juchnowski S; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.; Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA., Huntington L; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.; Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA., Jenkins T; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA., Nmai C; New York University Grossman School of Medicine, New York, New York, USA., Osnard M; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA., Shishebhor M; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA., Filby S; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA., Tatsuoka C; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA., Lederman MM; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA., Blackstone E; Department of Population Health and Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio, USA., Attizzani G; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA., Simon DI; Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.; Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
المصدر: Structural heart : the journal of the Heart Team [Struct Heart] 2023 Apr 28; Vol. 7 (4), pp. 100182. Date of Electronic Publication: 2023 Apr 28 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101743256 Publication Model: eCollection Cited Medium: Internet ISSN: 2474-8714 (Electronic) Linking ISSN: 24748706 NLM ISO Abbreviation: Struct Heart Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2022- : [New York] : Elsevier
Original Publication: Philadelphia, PA : Taylor & Francis Group, [2017]-
مستخلص: Background: Inflammation and thrombosis are often linked mechanistically and are associated with adverse events after transcatheter aortic valve replacement (TAVR). High residual platelet reactivity (HRPR) is especially common when clopidogrel is used in this setting, but its relevance to immune activation is unknown. We sought to determine whether residual activity at the purinergic receptor P2Y12 (P2Y12) promotes prothrombotic immune activation in the setting of TAVR.
Methods: This was a randomized trial of 60 patients (enrolled July 2015 through December 2018) assigned to clopidogrel (300mg load, 75mg daily) or ticagrelor (180mg load, 90 mg twice daily) before and for 30 days following TAVR. Co-primary endpoints were P2Y12-dependent platelet activity (Platelet Reactivity Units; VerifyNow) and the proportion of inflammatory (cluster of differentiation [CD] 14+/CD16+) monocytes 1 day after TAVR.
Results: Compared to clopidogrel, those randomized to ticagrelor had greater platelet inhibition (median Platelet Reactivity Unit [interquartile range]: (234 [170.0-282.3] vs. 128.5 [86.5-156.5], p < 0.001), but similar inflammatory monocyte proportions (22.2% [18.0%-30.2%] vs. 25.1% [22.1%-31.0%], p = 0.201) 1 day after TAVR. Circulating monocyte-platelet aggregates, soluble CD14 levels, interleukin 6 and 8 levels, and D-dimers were also similar across treatment groups. HRPR was observed in 63% of the clopidogrel arm and was associated with higher inflammatory monocyte proportions. Major bleeding events, pacemaker placement, and mortality did not differ by treatment assignment.
Conclusions: Residual P2Y12 activity after TAVR is common in those treated with clopidogrel but ticagrelor does not significantly alter biomarkers of prothrombotic immune activation. HRPR appears to be an indicator (not a cause) of innate immune activation in this setting.
Competing Interests: David A. Zidar reports research grant support from AstraZeneca, honoraria from GSK/Pfizer and Medtronic. Steven Filby is a consultant for Boston Scientific. Nicholas T. Funderburg is a consultant for Gilead. Mehdi Shishebhor is a consultant for Abbott Vascular, Medtronic, Terumo, Philips, and Boston Scientific. Sahil A. Parikh serves on the advisory Board of Abbott, Boston Scientific, Medtronic, Philips, Janssen, Cordis, Efemoral, and Advanced Nanotechnologies; receives research support from Abbott, Boston Scientific, surmodics, shockwave, and trireme; and is a consultant for Inari, Penumbra, Abiomed, and Terumo. Guilherme Attizzani is a consultant and advisory board member of Medtronic and Abbott Vascular. Daniel I. Simon reports honoraria from Medtronic.
References: J Am Coll Cardiol. 2021 Feb 2;77(4):450-500. (PMID: 33342587)
JACC Cardiovasc Interv. 2017 Jul 10;10(13):1357-1365. (PMID: 28527771)
JACC Basic Transl Sci. 2018 Aug 28;3(4):435-449. (PMID: 30175268)
J Am Coll Cardiol. 2017 Mar 14;69(10):1313-1346. (PMID: 28063810)
N Engl J Med. 2020 Oct 8;383(15):1447-1457. (PMID: 32865376)
Circ Cardiovasc Interv. 2017 Dec;10(12):. (PMID: 29222133)
J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):154-60. (PMID: 25647528)
JACC Cardiovasc Interv. 2013 Nov;6(11):1111-28. (PMID: 24262612)
J Am Coll Cardiol. 2013 Dec 17;62(24):2261-73. (PMID: 24076493)
J Am Heart Assoc. 2019 Jul 16;8(14):e011889. (PMID: 31267799)
Eur Heart J. 2021 Jun 14;42(23):2265-2269. (PMID: 33822924)
Ann Thorac Surg. 2009 Aug;88(2):468-74; discussion 474-5. (PMID: 19632395)
N Engl J Med. 2016 Apr 28;374(17):1609-20. (PMID: 27040324)
Front Immunol. 2019 Aug 30;10:2035. (PMID: 31543877)
N Engl J Med. 2009 Sep 10;361(11):1045-57. (PMID: 19717846)
JAMA. 2019 Jun 18;321(23):2306-2315. (PMID: 31211345)
Eur J Cardiothorac Surg. 2012 Nov;42(5):S45-60. (PMID: 23026738)
Eur Heart J. 2017 Sep 21;38(36):2739-2791. (PMID: 28886619)
Am J Cardiol. 2015 Dec 1;116(11):1731-6. (PMID: 26433275)
J Mol Histol. 2013 Jun;44(3):259-70. (PMID: 23359120)
Methods Find Exp Clin Pharmacol. 2006 Jun;28(5):315-22. (PMID: 16845449)
J Am Heart Assoc. 2015 Sep 21;4(9):e002096. (PMID: 26391132)
JACC Cardiovasc Imaging. 2016 Dec 8;:. (PMID: 28017712)
Blood. 2012 Nov 29;120(23):4599-608. (PMID: 23065151)
J Am Coll Cardiol. 2015 Jul 14;66(2):113-21. (PMID: 26055947)
N Engl J Med. 2015 Nov 19;373(21):2015-24. (PMID: 26436963)
J Am Coll Cardiol. 2013 Dec 24;62(25):2349-2359. (PMID: 23583252)
Circ Cardiovasc Interv. 2019 Feb;12(2):e007349. (PMID: 30732472)
J Am Coll Cardiol. 2013 Sep 10;62(11):1026-34. (PMID: 23644082)
J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):209-19. (PMID: 24414167)
N Engl J Med. 2012 May 3;366(18):1686-95. (PMID: 22443479)
Thromb Haemost. 2015 Aug 31;114(3):490-7. (PMID: 26156883)
PLoS One. 2017 Aug 22;12(8):e0183670. (PMID: 28829829)
N Engl J Med. 2017 Apr 6;376(14):1321-1331. (PMID: 28304219)
J Am Heart Assoc. 2017 Oct 17;6(10):. (PMID: 29042426)
Arterioscler Thromb Vasc Biol. 2013 Nov;33(11):2666-73. (PMID: 23968978)
Genes (Basel). 2020 Dec 16;11(12):. (PMID: 33339226)
Platelets. 2014;25(7):517-25. (PMID: 24127651)
Eur Heart J. 2011 Jan;32(1):84-92. (PMID: 20943670)
Eur Heart J. 2006 May;27(9):1038-47. (PMID: 16476694)
J Am Coll Cardiol. 2020 Aug 25;76(8):985-991. (PMID: 32819472)
JACC Cardiovasc Interv. 2019 Jan 14;12(1):22-32. (PMID: 30621974)
JACC Cardiovasc Interv. 2020 Nov 23;13(22):2601-2613. (PMID: 33069647)
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):340-6. (PMID: 22156911)
Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2562-70. (PMID: 26515417)
Circ Cardiovasc Interv. 2019 Jan;12(1):e007411. (PMID: 30630354)
Int J Cardiol. 2013 Oct 9;168(4):e118-20. (PMID: 23988301)
فهرسة مساهمة: Keywords: Clopidogrel; Inflammation; TAVR; Ticagrelor; Transcatheter aortic valve replacement
تواريخ الأحداث: Date Created: 20230731 Latest Revision: 20230801
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10382989
DOI: 10.1016/j.shj.2023.100182
PMID: 37520136
قاعدة البيانات: MEDLINE
الوصف
تدمد:2474-8714
DOI:10.1016/j.shj.2023.100182